FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS
Objective: In the first-in-man clinical study of intermittent intraputamenal monthly infusions of CDNF in subjects with moderately advanced PD, we explored cerebrospinal fluid (CSF) biomarkers…Reversible MIBG Abnormalities in Subjects at Risk for Synucleinopathy: 12 months data
Objective: To investigate the long-term effects of the adrenergic blocker carvedilol on I-MIBG myocardial uptake in subjects with REM sleep behavior disorder (RBD) and other…Randomised Controlled Trial Comparing Efficacy of Zonisamide 25 mg given in addition to standard treatment with standard treatment alone in Tremor dominant Parkinson’s Disease- A Pilot study.
Objective: To compare improvement in tremor at 12 weeks with Zonisamide given in a dose of 25 mg along with other ant- parkinsonian drugs as…Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1
Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models
Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results
Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis
Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…Influence of demographic characteristics on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the influence of baseline demographic characteristics (i.e., age and gender) on the response to opicapone (OPC) in Parkinson’s disease (PD)…Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of monoamine-oxidase-B…Local Field Potentials (LFP) used to guide treatment of biphasic dyskinesias in a patient with Parkinson’s Disease (PD)
Objective: To identify, characterize and treat dyskinesias and off time in a patient with PD via the use of gamma and beta peak LFP using…
- « Previous Page
- 1
- …
- 55
- 56
- 57
- 58
- 59
- …
- 132
- Next Page »